Sidoroff Marianne, Kolho Kaija-Leena
Children's Hospital, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.
Scand J Gastroenterol. 2012 Jul;47(7):745-50. doi: 10.3109/00365521.2012.679681. Epub 2012 Apr 17.
Children with moderate to severe inflammatory bowel disease (IBD) are treated with systemic glucocorticoids (GCs). The majority of the patients respond to the given treatment; however, steroid resistance and dependency are significant clinical problems. Also therapy-related side effects limit the use of GCs in the control of active inflammation. This review summarizes recent knowledge of GC treatment in pediatric patients with IBD.
中重度炎症性肠病（IBD）患儿采用全身性糖皮质激素（GCs）进行治疗。大多数患者对既定治疗有反应；然而，激素抵抗和依赖是严重的临床问题。此外，治疗相关的副作用限制了GCs在控制活动性炎症方面的应用。本综述总结了IBD患儿GC治疗的最新知识。
